Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer (Q43478484)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 August 2013

Language	Label	Description	Also known as
English	Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer	scientific article published on 17 August 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

Ralf Lesche

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Georg Kettschau

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Alexey V Gromov

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Niels Böhnke

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sandra Borkowski

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Ursula Mönning

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Christa Hegele-Hartung

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Olaf Döhr

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Ludger M Dinkelborg

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Keith Graham

10

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

publication date

17 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

number of pages

13

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

89-101

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

https://scigraph.springernature.com/pub.10.1007/s00259-013-2527-3

0 references

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Choline PET and PET/CT in Primary Diagnosis and Staging of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Kinetics of [(11)C]choline uptake in prostate cancer: a PET study.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Prostate-specific membrane antigen: present and future applications

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Radionuclide based imaging of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Physical models and dose factors for use in internal dose assessment

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Decay data for internal and external dose assessment

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Suitability of commonly used excipients for electrophysiological in-vitro safety pharmacology assessment of effects on hERG potassium current and on rabbit Purkinje fiber action potential

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

In vitro safety pharmacology profiling: what else beyond hERG?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

QTc shortening with a new investigational cancer drug: a brief case study

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Immunocytochemical distribution of N-acetylaspartylglutamate in the rat forebrain and glutamatergic pathways.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Decreased replication ability of E1-deleted adenoviruses correlates with increased brain tumor malignancy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

4-[18F]fluoroglutamic acid (BAY 85-8050), a new amino acid radiotracer for PET imaging of tumors: synthesis and in vitro characterization.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

[Diagnostic relevance of choline-PET / CT in patients with prostate cancer].

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2527-3

21 January 2018

Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific membrane antigen expression in normal and malignant human tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Novel role of prostate-specific membrane antigen in suppressing prostate cancer invasiveness.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A tabulated summary of the FDG PET literature.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Promising tumor-associated antigens for future prostate cancer therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23955632

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-013-2527-3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

release_rurvrfbsjza37lrjx73vsdwscm

1 reference

https://api.fatcat.wiki/v0/release/rurvrfbsjza37lrjx73vsdwscm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43478484&oldid=1989655778"